Cas:41202-77-1 1-(2,3-DICHLOROPHENYL)PIPERAZINE manufacturer & supplier

We serve Chemical Name:1-(2,3-DICHLOROPHENYL)PIPERAZINE CAS:41202-77-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-(2,3-DICHLOROPHENYL)PIPERAZINE

Chemical Name:1-(2,3-DICHLOROPHENYL)PIPERAZINE
CAS.NO:41202-77-1
Synonyms:MFCD00190238;Piperazine, 1-(2,3-dichlorophenyl)-;1-(2,3-DICHLOROPHENYL)PIPERAZINE;N-(2,3-Dichlorophenyl)piperazine;T6M DNTJ DR BG CG;1-(2,3-Dichlorophenyl)-piperazine hydrochloride
Molecular Formula:C10H12Cl2N2
Molecular Weight:231.122
HS Code:2933599090

Physical and Chemical Properties:
Melting point:242-244ºC
Boiling point:365.1±42.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.570
PSA:15.27000
Exact Mass:230.037750
LogP:2.89

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like MFCD00190238 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(2,3-Dichlorophenyl)-piperazine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(2,3-Dichlorophenyl)piperazine Use and application,1-(2,3-Dichlorophenyl)-piperazine hydrochloride technical grade,usp/ep/jp grade.


Related News: Japan on Friday approved the administration of AstraZeneca Plc’s (AZN.L) COVID-19 vaccine after a few months’ pause due to fears about potential side effects, local media reported. 4-methyl-1-decanol manufacturers Meanwhile, EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Moderna’s Covid-19 vaccine, now known as Spikevax, to include adolescents 12 years of age and older. 6-chloro-3-(2-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine suppliers The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 10(9H)-Acridinepropanamine, 9-ethylidene-3,4-dimethyl- vendor & factory.